Ipsen’s partner Inspiration Biopharmaceuticals announces the treatment of the first patient in phase III pivotal study of OBI-1 for acquired hemophilia A

Understanding the true impact of living with FOP

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Applications now open for the 2023 Golden Ticket Competition

Offering support to those impacted in Turkey & Syria